Quetiapine Tablet, Extended Release
Product Images NDC 33342-137

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Quetiapine (NDC 33342-137). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Quetiapine 150mg 500 S

Quetiapine Extended-Release Tablets USP 150 mg, oral extended-release tablets manufactured by Macleods Pharmaceuticals Limited. The label includes dosage instructions stating once daily use, storage conditions between 20° to 25°C, and a warning to keep out of reach of children. The package contains 500 tablets and is labeled with NDC 33342-134-15 and Macleods Pharma USA as the distributor.*

FDA Label Image

Quetiapine-150mg-60s (Quetiapine 150mg 60s)

The label for Quetiapine Extended-Release Tablets, USP, 150 mg strength, by Macleods Pharmaceuticals Limited. It includes the dosage form as orally administered extended-release tablets, specifying each tablet contains 150 mg quetiapine. The label states to swallow whole and dosage as once daily, with storage instructions at controlled room temperature. The package contains 60 tablets.*

FDA Label Image

Quetiapine 200mg 500 S

Label for Quetiapine Extended-Release Tablets, USP 200 mg, manufactured by Macleods Pharmaceuticals Limited. The label includes dosage instructions indicating once daily use, storage conditions, pharmacist dispensing guidance, and tablet count of 500 tablets. It states each 200 mg tablet contains 230.26 mg quetiapine fumarate equivalent to 200 mg quetiapine.*

FDA Label Image

Quetiapine-200mg-60s (Quetiapine 200mg 60s)

Label for Quetiapine Extended-Release Tablets USP 200 mg by Macleods Pharmaceuticals Limited. The oral extended-release tablets come in a bottle of 60 count. The label includes dosage instructions (once daily), storage conditions, and warnings, with manufacturer details from Macleods Pharma USA and Macleods Pharmaceuticals Ltd., India.*

FDA Label Image

Quetiapine 300mg 500 S

Label for Quetiapine Extended-Release Tablets, USP 300 mg by Macleods Pharmaceuticals Limited. The label instructs a once daily dosage with each 300 mg tablet containing quetiapine fumarate equivalent to 300 mg quetiapine. It includes storage conditions, pharmacist dispensing instructions, and a warning to keep out of reach of children. The package contains 500 tablets.*

FDA Label Image

Quetiapine-300mg-60s (Quetiapine 300mg 60s)

Label for Quetiapine Extended-Release Tablets, USP 300 mg by Macleods Pharmaceuticals Limited. The oral extended-release tablet packaging indicates each 300 mg tablet contains 345.38 mg of quetiapine fumarate equivalent to 300 mg quetiapine. The label includes usage instructions, storage conditions (20° to 25°C standard with excursions 15° to 30°C), and a warning to keep out of reach of children. The package contains 60 tablets.*

FDA Label Image

Quetiapine 400mg 500 S

Label for Quetiapine Extended-Release Tablets USP 400 mg by Macleods Pharmaceuticals Limited. The label includes dosing instructions as once daily, storage conditions, and active ingredient content of each 400 mg tablet. It indicates packaging of 500 tablets and displays barcodes and manufacturing information for Macleods Pharma USA and Macleods Pharmaceuticals Ltd India.*

FDA Label Image

Quetiapine-400mg-60s (Quetiapine 400mg 60s)

Packaging label for Quetiapine Extended-Release Tablets, USP 400 mg, oral dosage form. The label indicates each tablet contains 460.50 mg quetiapine fumarate equivalent to 400 mg quetiapine. The bottle contains 60 tablets and is labeled for Macleods Pharmaceuticals Limited. Instructions note to swallow whole without crushing or chewing and usual dosage is once daily. Storage conditions specify 20° to 25°C with permitted excursions.*

FDA Label Image

Quetiapine-fig-1 (Quetiapine Fig 1)

Chemical structure of quetiapine. The diagram shows the molecular structure of quetiapine, including its heterocyclic components and functional groups, as part of the extended-release formulation.*

FDA Label Image

Quetiapine-fig-2 (Quetiapine Fig 2)

A line graph showing the proportion of patients with relapse (%) over time (months) comparing two groups: PLA and QTF XR. The graph depicts relapse rates increasing more rapidly in the PLA group than in the QTF XR group over a 12-month period.*

FDA Label Image

Quetiapine-fig-3 (Quetiapine Fig 3)

A line graph showing the proportion of patients with relapse over time (weeks). Two lines compare QTP + LIVAL and PLA + LIVAL groups, illustrating differences in relapse rates during the study period up to 80 weeks.*

FDA Label Image

Quetiapine-fig-4 (Quetiapine Fig 4)

A line graph showing the proportion of patients with relapse (%) over time (weeks) up to 100 weeks. Two groups are compared, labeled as 'QTP+LIVAL' and 'PLA+LIVAL,' with 'QTP+LIVAL' showing a higher relapse proportion over time compared to 'PLA+LIVAL.'*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.